肺癌治疗药物~(90)Y-DTPA-McAbD_2的合成

摘要: 对单克隆抗体Ｄ＿２（ＭｃＡｂＤ＿２）与环化ＤＴＰＡ酸酐（ＣＤＴＰＡＡ）偶联的方法和￣（９０）Ｙ标记单克隆抗体０２（ＭｃＡｂＤ＿２）的条件进行了研究，结果表明：在标记抗体￣（９０）Ｙ－ＤＴＰＡ－ＭｃＡｂＤ＿２（肺癌治疗药物）比活度为３．７×１０￣４Ｂｑ／μｇ时，标记率＞９０％。标记抗体￣（９０）Ｙ－ＤＴＰＡ－ＭｃＡｂＤ＿２放化纯度＞９８％，在体外有很好的稳定性，并且有７３％的免疫活性，可用于临床研究。

Abstract: SYNTHESUS OF LUNG CANCER`s THERAPY PHARMACEUTICAL~(90)Y-DTpA-McAbD_2 Lj Yunchun Guang Changtian（First Affilicated Hospital of west China University of Medical Sciences, Chengdu 610041）Ma Chongzhi Jing Lie（China Institute of Atomic Energy,beijing 102413）ABSTRACT The coupling of monoclonal antitheies D_2（McAbD_2）to bicyclic DTPA anhydride（CDTPAA）and the methed of labeling monoclonal antibodies D_2 with~(90) Y have been studied．The resuIts have showed that when McAbD_2 is labeled with~(90) Y the specific activity of labeled antibodies is 3．7×10~4 Bq／μg，the radiochemical purity is more than 98％，the labeling efficiency is more than 90％，and have a good stability in vitro and immunological activity of 73％.Key words bicyclic DTPA anhydride（CDTPAA）monoclonal antibodies D_2（McAbD_2）couple ~(90)Y label immunological activity